(Q40479634)

20 September 2017

title

A phase I study of flavopiridol and docetaxel. (English)

1 reference

20 September 2017

Basil F El-Rayes

1

1 reference

20 September 2017

Shirish Gadgeel

2

1 reference

20 September 2017

Ralph Parchment

3

1 reference

20 September 2017

Patricia Lorusso

4

1 reference

20 September 2017

Philip A Philip

5

1 reference

20 September 2017

publication date

1 July 2006

1 reference

Investigational New Drugs

20 September 2017

published in

1 reference

20 September 2017

volume

24

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

305-310

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-005-4343-5

20 September 2017

exact match

0 references

cites work

Clinical pharmacokinetics of docetaxel.

1 reference

12 December 2020

Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.

1 reference

12 December 2020

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

1 reference

12 December 2020

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

12 December 2020

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

12 December 2020

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

1 reference

12 December 2020

Taxanes: a new class of antitumor agents.

1 reference

12 December 2020

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

12 December 2020

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

1 reference

12 December 2020

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

1 reference

12 December 2020

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

12 December 2020

Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

1 reference

12 December 2020

Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography

1 reference

12 December 2020

Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol.

1 reference

12 December 2020

Docetaxel: overview of an active drug for breast cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells

1 reference

12 December 2020

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

12 December 2020

Mechanisms of action of flavopiridol

1 reference

12 December 2020

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S10637-005-4343-5

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1010047253

0 references

1 reference